<DOC>
	<DOCNO>NCT00668408</DOCNO>
	<brief_summary>In patient COPD CHF , moderate chronic hypoxemia cause combination intrapulmonary extrapulmonary factor . The hypothesis study adequate medical therapy condition correct moderate hypoxemia improve underlying mechanism without need LTOT . If hypothesis correct , study provide valuable information Italian Agency drug ( Agenzia Italiana del Farmaco , AIFA ) reduce inappropriate use LTOT COPD patient moderate hypoxemia CHF , help Italian National Health Service reduce direct indirect cost unnecessary LTOT .</brief_summary>
	<brief_title>LTOT COPD Patients With Moderate Chronic Hypoxemia Chronic Heart Failure</brief_title>
	<detailed_description>Long-term oxygen treatment ( LTOT ) improve survival COPD patient severe hypoxemia . The improved survival proven COPD patient severe chronic hypoxemia ( PaO2 &lt; = 55 mmHg ) , provide oxygen deliver = &gt; 15 hours/day . Since , &gt; 15 hours/day LTOT become standard treatment COPD patient severe hypoxemia . LTOT extend without evidence COPD patient moderate hypoxemia ( 55 &lt; PaO2 &lt; 60mmHg ) , associate clinical laboratory sign cardiac disease patient decrease oxygen saturation ( SO2 &lt; 90 % ) exercise sleep . Chronic heart failure ( CHF ) common co-morbidity COPD ( &gt; 30 % ) particularly elderly . Whether LTOT improve survival patient moderate chronic hypoxemia CHF unknown . This issue concern potential importance LTOT severe COPD , cost LTOT ( Euro 250 millions/year Italy ) . The aim 3 year randomize clinical trial investigate whether , COPD patient moderate hypoxemia associate CHF treatment include LTOT different treatment without LTOT term survival exacerbation , hospitalization , quality life . The study conduct 76 Italian hospital pulmonary unit , start May 15th 2008 end October 31st 2012 . One thousand stable COPD patient treat accord COPD CHF international guideline randomize treatment include LTOT ( Study Group ) treatment without LTOT ( Control Group ) . All patient regularly undergo clinical assessment , arterial blood gas ( 3 monthly ) , Saint George 's Respiratory Questionnaire ( SGRQ , 6 monthly ) , contact monthly telephone call . Considering 1 ) lack evidence support LTOT COPD patient moderate hypoxemia CHF , 2 ) pathophysiology CHF , 3 ) improvement pharmacological treatment COPD CHF , expect , optimization medical therapy , LTOT improve survival frequency severity exacerbation and/or hospitalization , even quality life due balance small clinical benefit ( improve exercise tolerance , good sleep ) inconvenience associate LTOT . This non-inferiority study power survival , primary outcome study .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Anoxia</mesh_term>
	<criteria>Age 40 &gt; 80 year Confirmed COPD ( GOLD criterion ) Moderate stable hypoxemia ( 55 &lt; PaO2 &lt; 65 mmHg ) Clinical sign CHF ( ESC criterion ) Exsmokers ( &gt; 20 pack/years ) since least 3 month Clinical instability and/or exacerbation Congenital heart diseases Lung cancer Thoracic restrictive disorder Other coexist disease influence 3yr survival</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>OTLT</keyword>
	<keyword>COPD</keyword>
	<keyword>CHRONIC HYPOXEMIA</keyword>
	<keyword>CHF</keyword>
</DOC>